| Literature DB >> 23173732 |
Harald Essig1, Riaz Warraich, Gulraiz Zulfiqar, Madiha Rana, André Michael Eckardt, Nils-Claudius Gellrich, Majeed Rana.
Abstract
BACKGROUND: Cervical metastasis has a tremendous impact on the prognosis in patients with carcinomas of the head and neck and the frequency of such spread is greater than 20% for most squamous cell carcinomas. With emerging evidence, focus is shifting to conservative neck procedures aimed at achieving good shoulder function without compromising oncologic safety. The purpose of this study was to analyze the pattern of nodal metastasis in patients presenting with squamous cell carcinoma of buccal mucosa.Entities:
Mesh:
Year: 2012 PMID: 23173732 PMCID: PMC3514153 DOI: 10.1186/1477-7819-10-253
Source DB: PubMed Journal: World J Surg Oncol ISSN: 1477-7819 Impact factor: 2.754
Patient’s preoperative demographic data
| Age 25 to 75 years, irrespective of gender | Previously operated |
| Histopathologically proven cases of squamous cell carcinoma of buccal mucosa | Systemic metastasis (detected by means of chest X-ray, abdominal ultrasound, and CT scan) |
| Primary tumor site in oral cavity is buccal mucosa | Unfit for general anesthesia |
| Clinical tumor size T2 to T4 | Previously irradiated |
| Lymph node involvement: N1 (clinically and with sonographic examination) | Without written informed consent |
Figure 1(A) demonstrates the margins of all resected specimens of primary tumor and cervical lymph nodes. Level I was marked with one silk string, level II with two silk strings, level III with three silk strings, level IV with four silk strings, and level V with five silk strings, (B) a 51-year-old patient with a squamous cell carcinoma of buccal mucosa and clinically proven N1 neck.
Figure 2Metastatic lymph node was the highest, that is, level I was 100% (44/44), level II was 43.18% (19/44), level III was 15.90% (7/44) and level IV was 3% (2/44). Level V was free of metastasis.
Baseline characteristics
| | |
|---|---|
| Age (mean ± sd) | 56.55 ± 5.48 |
| | |
| Male | 45 (75) |
| Female | 15 (25) |
| | |
| Never | 10 (16.6) |
| Previous | 16 (26.7) |
| Actual | 34 (56.7) |
| | |
| Never | 39 (65) |
| ≤20 g/d | 13 (21.7) |
| 21 to 40 g/d | 4 (6.7) |
| 41 to 60 g/d | 2 (3.3) |
| 61 to 80 g/d | 0 (0) |
| Unknown | 2 (3.3) |
| | |
| Yes | 52 (86.7) |
| No | 8 (13.3) |
| | |
| T2 | 6 (10) |
| T3 | 10 (16.7) |
| T4 | 44 (73.3) |
Metastatic lymph node levels
| Level I | 40 | 66.7% |
| Levels I, II | 13 | 21.7% |
| Levels I, II, III | 5 | 8.3% |
| Levels I, II, III, and IV | 2 | 3.3% |
| Total | 60 | 100% |